From: Efficacy and safety of catheter ablation for atrial fibrillation in patients with history of cancer
Variables | OR (95% CI) | P value |
---|---|---|
Age | 0.99 (0.94–1.03) | 0.62 |
Female | 1.23 (0.52–2.91) | 0.64 |
BMI | 1.08 (1.03–1.15) | 0.002 |
Hypertension | 0.25 (0.11–0.57) | 0.001 |
Hyperlipemia | 1.40 (0.64–3.09) | 0.40 |
Diabetes | 0.72 (0.25–1.97) | 0.52 |
Obstructive sleep apnoea | 0.82 (0.37–1.81) | 0.63 |
Coronary artery disease | 0.45 (0.15–1.26) | 0.14 |
Paroxysmal atrial fibrillation | 0.57 (0.27–1.21) | 0.14 |
Long term persistent atrial fibrillation | 1.11 (0.21–5.87) | 0.90 |
CHA2DS2-VASc score | 1.32 (0.97–1.83) | 0.08 |
Pulmonary vein isolation plus lines | 1.39 (0.68–2.85) | 0.36 |
Cryoablation | 1.09 (0.52–2.28) | 0.82 |
Radiofrequency + Cryoablation | 0.49 (0.10–2.06) | 0.34 |
Anthracycline exposure | 0.62 (0.24–1.54) | 0.31 |
Thoracic radiation | 0.37 (0.15–0.86) | 0.02 |
Multiple malignancies | 0.89 (0.32–2.31) | 0.81 |